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Cystatin C is being considered as a replacement for serum
creatinine in the estimation of the glomerular filtration rate
(GFR); however, its plasma levels might be affected by factors
other than the GFR, such as protein intake. We performed a
post hoc analysis of the data in the Modification of Diet in
Renal Disease study, in which we compared serum creatinine
and cystatin C levels in 741 patients with available estimates
of protein intake at baseline prior to their randomization to
diets containing various amounts of protein, and at 2 years
of follow-up in 426 of these patients in whom a cystatin C
measurement was available. The 503 patients in study A
(GFR 25–55ml/min per 1.73m2) had been assigned a low
(0.58 g/kg per day) or a usual (1.3g/kg per day) protein
intake, and the 238 participants in study B (GFR 13–24ml/min
per 1.73m2) were assigned a very low (0.28g/kg per day) or
the low protein intake. In either study group, lowering the
dietary protein intake reduced the change in creatinine,
but did not have a significant change in cystatin C. Thus, in
patients with moderate-to-severe chronic kidney disease,
serum cystatin C unlike serum creatinine was not affected by
dietary protein intake independent of changes in GFR. Hence,
cystatin C may allow more accurate estimates of GFR than
creatinine for patients with reduced protein intake. Further
study of other non-GFR determinants of cystatin C is needed
before the widespread adoption.
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Accurate estimation of the glomerular filtration rate (GFR) is
essential for the diagnosis, staging, and management of
chronic kidney disease (CKD).1,2 Serum creatinine is most
commonly used to estimate GFR, with current estimating
equations taking into account age, sex, race, and weight as
non GFR determinants of creatinine.3,4
Cystatin C is being proposed as potentially superior
biomarker for GFR estimation.5 Cystatin C is an endogenous
13 kDa protein that is freely filtered at the glomerulus,
and then nearly completely reabsorbed and catabolized by
proximal tubular epithelial cells with only small amounts
excreted in the urine. Cystatin C generation is felt to be
constant, thus serum levels are not affected by variables other
than kidney function.6 Therefore, cystatin C is felt to be a
promising candidate for replacing creatinine as a biomarker
for estimating GFR.
More recent studies, however, have found variability in the
relationship between cystatin C and measured GFR suggest-
ing the potential for non-GFR determinants of cystatin C.7–9
Understanding these potential determinants would be
important to develop and evaluate GFR estimating equations
based on cystatin C and to better understand the relationship
between cystatin C and adverse outcomes.
To address this question, we analyzed data from the
Modification in Diet and Renal Disease (MDRD) study, which
was a randomized controlled trial of protein restriction and
blood pressure control in patients with CKD stages 3 and 4.7
We examined the relationship between dietary protein intake
and creatinine and cystatin C levels at baseline after adjustment
for measured GFR and GFR measurement error. In addition,
we tested the effect of a dietary protein intake prescription on
creatinine and cystatin C independent of GFR in a longitudinal
analysis comparing randomized groups.
RESULTS
Study population
Baseline characteristics of the study population are presented
in Table 1. Cystatin C measurements were available in 574
out of 585 patients in study A and 251 out of 275 patients in
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study B at the time of randomization. The mean measured
GFR at time of randomization was 38.6ml/min per 1.73m2
in study A and 18.5ml/min per 1.73m2 in study B.
The etiology of kidney disease included polycystic kidney
disease (22%), glomerular disease (27%), hypertensive
nephrosclerosis (17%), tubulointerstitial diseases (7%), and
other or unknown (14%). Only 3.5 % of the patients had
diabetic nephropathy, because patients with diabetes requir-
ing insulin were excluded from the MDRD study. Estimated
protein intake (EPI) was slightly higher in study A compared
with study B.
In all, 84 patients (10%) did not have 24-h urine
collections available at the final baseline visit for determina-
tion of EPI, and were therefore excluded from the cross-
sectional analysis. A higher proportion of men and patients
from study A were missing EPI at baseline. Patients with
missing EPI also had slightly lower values for creatinine
and cystatin C and higher measured GFR (Appendix A,
Table A1). Over the follow-up period of 2 years, 23 patients
died and 86 went on to develop kidney failure. Cystatin
C measurements were available in 426 patients at 2 years,
with 290 patients missing cystatin C measurements at
follow-up. These patients had no statistically significant
differences in age, etiology of kidney disease, and proteinuria,
from the group with available cystatin C measurements.
Small differences in measured GFR and EPI were again
observed (Appendix A, Table A2).
Cross-sectional analysis
The cross-sectional associations relating EPI to serum
creatinine and cystatin C are presented in Table 2. EPI was
more strongly associated with serum creatinine than cystatin
C at baseline after adjustment for GFR, GFR measurement
error, age, sex, and race; a 0.2 g/kg per day higher EPI was
associated with a 2.4 (0.6)% higher serum creatinine and a
0.9 (0.6)% higher cystatin C. The association for creatinine,
but not cystatin C, was statistically significant.
Longitudinal analysis
A longitudinal analysis of randomized groups is presented in
Table 3 and Figure 1. The change in measured GFR from
baseline to year 2 was identical in the usual and low protein
diet groups (0.3ml/min per 1.73m2 in study A and
0.2ml/min per 1.73m2 in study B). In study A, the change
in serum creatinine was lower (0.22 (0.36, 0.08) mg/dl)
in the low protein intake arm compared with the usual
protein intake arm. Consequently, the change in the
creatinine-based GFR estimate was higher (2.2 (0.6, 3.9)
ml/min per 1.73m2) in the low protein intake arm compared
with the usual protein intake arm. In study B, the changes in
serum creatinine levels and the creatinine-based GFR
estimate did not differ significantly between the low and
very low protein diet (0.28 (0.82, 0.21) mg/dl and 0.8
(1.0, 2.6) ml/min per 1.73m2, respectively). Changes in the
serum cystatin C concentration and the cystatin-based GFR
estimate did not differ between randomized groups in either
study.
Performance of estimating equations
A comparison of the performance of the MDRD study
equation and the CKD–EPI cystatin C 2008 equation at
baseline and at 2 years for the treatment groups is presented
in Table 4. When computing estimated GFR (eGFR) using
serum creatinine, in study A, the difference in bias between
the low and usual protein diet groups was not significantly
different at baseline, (0.23 (1.61, 1.15) ml/min per 1.73m2)
but was significantly greater in the low protein diet group at
follow-up (2.77 (4.08, 1.48) ml/min per 1.73m2),
reflecting a greater overestimation of measured GFR in the
low protein diet group. In study B the results were
qualitatively similar, although the difference at follow-up
was not statistically significant. The relative change in bias,
compared with mean baseline mGFR, was 8.01% in study A
and 7.44% in study B. In contrast, when computing eGFR
using serum cystatin C, there was no difference in bias
between randomized groups at either baseline or follow-up in
study A or study B, and no change over time (o1ml/min per
1.73m2 and o2.5%).
Table 1 | Baseline characteristics of the study population
Study A (574) Study B (251)
Mean/Na s.d./% Mean/N s.d./%
Age (years) 52.0 12.2 50.9 12.9
Female 224 61.0 102 40.6
White 52 9.1 13.0 5.2
Smoking status
Regularly 55 10.7 28 12.2
Occasionally 281 54.5 111 48.3
Never 139 24.2 59 23.5
Systolic blood pressure (mmHg) 131.4 17.5 133.1 17.7
Diastolic blood pressure (mmHg) 81.0 10.0 80.9 10.3
Etiology of kidney disease
Polycystic kidney disease 139 24.2 59 23.5
Hereditary nephritis and
tubulointerstitial disease
175 30.5 74 29.5
Hypertensive kidney disease 100 17.4 39 15.5
Diabetic nephropathy 17 3.0 9 3.6
Glomerular disease 143 24.9 70 27.9
Laboratory data
Serum creatinine (mg/dl) 1.9 0.5 3.4 0.9
Serum cystatin C (mg/l) 1.9 0.4 3.0 0.5
Measured GFR
(ml/min per 1.73m2)
38.6 8.9 18.5 3.4
Proteinuria (g/day) 1.0 1.6 1.4 1.7
Serum albumin (g/dl) 4.0 0.3 4.0 0.4
Serum CRP (mg/l) 0.5 0.6 0.4 0.6
Estimated protein intake
(g/kg per day)b
1.1 0.2 0.9 0.2
Abbreviations: CRP, C-reactive protein; GFR, glomerular filtration rate.
aData are presented as mean±s.d. for continuous variables and N/percentage for
categorical variables.
bProtein intake estimated from urine urea nitrogen excretion rate was available for
741/825 participants.
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DISCUSSION
In this study of a dietary protein intake intervention in
patients with moderate-to-severe CKD, we found that serum
cystatin C, unlike serum creatinine, is not affected by dietary
protein intake independent of changes in GFR. Consequently,
the creatinine-based GFR estimate but not the cystatin-based
GFR estimate is affected by protein intake, and an estimating
equation based on cystatin C is more accurate than an
estimating equation based on serum creatinine in patients
ingesting a low protein diet. Our findings suggest that
cystatin C may be a better filtration marker in patients with
CKD and decreased protein intake.
Cystatin C is being increasingly proposed as a replacement
for serum creatinine as an endogenous marker of GFR.5,6
However, before the widespread adoption of cystatin
C measurements in clinical practice, it is necessary to
understand its non-GFR determinants. Non-GFR determi-
nants of endogenous filtration markers include generation,
renal tubular reabsorption and secretion, and extra-renal
elimination.8 Knowledge of these determinants can aid the
interpretation of cystatin C levels, and facilitate development
of GFR estimating equations based on cystatin C.
The non-GFR determinants of serum creatinine have been
well studied in diverse patient populations.9 Studies examin-
ing creatinine generation and excretion have shown that these
parameters can vary with dietary protein intake and blood
pressure interventions. These studies have also demonstrated
that creatinine based outcomes may be misleading in
interpretation of randomized controlled trials of dietary
protein intake restriction.10 However, unlike creatinine,
cystatin C is not excreted in the urine, making it difficult
to study differences in its non-GFR determinants, leaving
epidemiological studies as the usual method to infer the
contribution of non GFR determinants to variation in
cystatin C. These epidemiological studies have demonstrated
that the previous assumptions regarding the constant rate of
generation of cystatin C may not be valid. Small studies
showing associations of cystatin C with inflammatory
markers and markers of metabolism (thyroid hormone
levels) also suggest that cystatin C generation may not be
constant.11 Furthermore, studies in non-renal inflammatory
diseases, such as asthma, have demonstrated changes in
cystatin C with disease activity and with immunosuppressive
medications such as steroids and calcineurin inhibitors.12,13
On a population scale, data from the National Health and
Nutrition Examination Survey have shown variability
in cystatin C levels with age and race, reflecting the role of
possible non-GFR determinants and potential confounders
in the relationship between cystatin C and GFR. Other
epidemiologic studies, including studies of the Prevention of
Renal and Vascular End Stage Disease (PREVEND) cohort,
have also found associations between greater height and
weight and cystatin C levels.14,15 These studies, however, used
serum creatinine or measured creatinine clearance, rather
Table 2 | Association of estimated protein intake with creatinine and cystatin C at baselinea
Not adjusted Adjusted for GFR
Adjusted for GFR
measurement error 0.015
Adjusted for GFR measurement
error (0.015), age, sex, and raceb
N Coeff (s.d.) P-value Coeff (s.d.) P-value Coeff (s.d.) P-value Coeff (s.d.) P-value
Serum creatinine (%) 741 0.141 (0.010) o0.001 0.006 (0.008) 0.45 0.012 (0.008) 0.145 0.024 (0.006) o0.001
Serum cystatin C (%) 741 0.110 (0.009) o0.001 0.007 (0.006) 0.26 0.022 (0.006) o0.001 0.009 (0.006) 0.13
Abbreviations: Coeff, coefficient; GFR, glomerular filtration rate.
aProtein intake is estimated from urine urea nitrogen, cystatin, and creatinine are log transformed.
bInterpretation: after adjustment for GFR, age, race and sex, and GFR measurement error, a 0.2 g/kg per day increase in baseline protein intake is associated with a 2.4 (0.6)%
higher baseline serum creatinine and a 0.9 (0.6)% higher baseline serum cystatin C.
Table 3 | Effect of prescribed dietary protein on change in
measured GFR, creatinine, and cystatin C independent of
GFR, and estimated GFR using creatinine and cystatin Ca
Study A (n=302) Study B (n=124)
DGFR (ml/min per 1.73m2) 0.3 (2.1, 1.6) 0.2 (1.9, 1.4)
DSerum creatinine (mg/dl) 0.22 (0.36, 0.08) 0.28 (0.82, 0.21)
DeGFRcr (ml/min per 1.73m2) +2.2 (0.6, 3.9) + 0.8 (1.0, 2.6)
DSerum cystatin C (mg/l) 0.02 (0.08, 0.13) 0.10 (0.15, 0.26)
DeGFRcys (ml/min per 1.73m2) 0.4 (2.1, 0.9) 0.3 (1.5, 2.2)
Abbreviations: eGFRcr, creatinine-based glomerular filtration rate estimate; eGFRcys,
cystatin-based glomerular filtration rate estimate; GFR, glomerular filtration rate.
aDifferences between randomized groups (change in low protein diet group minus
change in usual protein diet group in study A; very low minus low protein
diet group). Change is defined as 24-month baseline. Changes in creatinine and
cystatin C, and eGFR measurements are adjusted for change in measured GFR.
All values are reported as mean and 95% confidence interval. Values highlighted
in boldface font are statistically significant with Po0.01.
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Figure 1 |Change in creatinine, cystatin C and measured
glomerular filtration rate (GFR) in study A over the follow-up
period. Absolute values for creatinine, cystatin C, and GFR are shown.
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than measured GFR, to adjust for GFR, and therefore, may
have been susceptible to confounding from non-GFR
determinants of creatinine and creatinine clearance.
In contrast, our findings regarding the lack of association
of EPI with cystatin C differ from the previous literature on
cystatin C and nutritional markers.
In our own previous study using a cross-sectional analysis
of the pooled dataset from the CKD–EPI collaboration, which
included the MDRD study, after adjustment for GFR, there
was a 6.5% higher serum creatinine and a 4% higher serum
cystatin C for each 4.7 g/day higher urine urea nitrogen,
equivalent toB1.5 and is 1% higher serum levels per 0.2 g/kg
per day higher EPI.16 In this study, after adjustment for GFR
and GFR measurement error, we similarly found a positive
association with cystatin C in our cross-sectional analysis,
which replicates the findings from the previous study,
however in longitudinal analysis, dietary protein prescription
did not affect cystatin C. This suggests that the positive
associations with cystatin C and protein intake observed in
the cross-sectional analyses likely reflect associations with
unmeasured confounders, which were balanced in the
randomized design, highlighting the strengths of our long-
itudinal analysis.
Our findings have implications in the clinical care and in
research of patients with protein energy malnutrition and
CKD. Protein energy malnutrition, because of the underlying
uremia, has been well documented in the advanced stages of
CKD.17–19 The effect of decreased protein intake to lower
creatinine generation, independent of GFR, can lead to falsely
low GFR estimates using creatinine in patients with advanced
CKD and protein energy malnutrition. In the presence of
a true decline in GFR and underlying uremia leading to
diminished protein intake, using serum creatinine to estimate
GFR in these patients can lead to a false assumption of stable
disease and may delay appropriate preparation for or
initiation of renal replacement therapy. Cystatin C, on the
other hand, does not seem to be affected by dietary protein
intake and therefore, may be a better endogenous filtration
marker in these patients.20 On average, we found a
differential bias between the creatinine- and cystatin-based
GFR estimates of B7–8%. In clinical practice, with larger
reductions in protein intake, the differential bias in GFR
estimates is likely to be greater. In principle, if the clinician
suspects that a GFR estimate is unreliable, then it is
important to have a confirmatory test. At this time, the only
confirmatory test for eGFR is based on serum creatinine
is measured GFR using either exogenous filtration markers
or a timed urine collection; both have limitations. Our results
identifies cystatin C as a potential filtration marker to as a
confirmatory test for GFR estimates based on serum
creatinine in patients ingesting a low protein diet. In
addition, using the change in the cystatin-based GFR estimate
instead of the creatinine-based GFR estimate, as an outcome
measure in a clinical trial of a protein intake intervention can
avoid potentially misleading conclusions.
The strengths of our study are that we used measured GFR
as a covariate to examine the true independent effect of a
dietary protein intervention on cystatin C in a well-
characterized, randomized controlled trial of patients with
moderate-to-severe CKD. We were able to adjust for
measured GFR and GFR measurement error, further adding
to the precision of our findings. Finally, we also examined the
effect of the dietary protein intake intervention on the
performance of the MDRD study equation and the CKD–EPI
cystatin C 2008 equation.
Our analysis has some limitations: The MDRD study
included patients with moderate to severe CKD, and as a
result, a significant number of patients progressed to kidney
failure or were censored because of the death at our follow-
up time of 2 years. Our findings, therefore, may not be
generalizable to those who died or those who progressed
rapidly to kidney failure. Second, a significant proportion of
our baseline cohort (N¼ 290) did not have cystatin C levels
available at the 2 year follow-up. (Appendix A, Table A1)
These patients, were therefore, only analyzed in the cross-
sectional arm of the study and did not participate in the
longitudinal analysis of randomized groups. Although we did
not observe clinically significant differences in age, etiology of
kidney disease, proteinuria, and measured GFR in this group
compared with our longitudinal study sample (N¼ 426),
differences in unmeasured confounders may exist. Finally, the
MDRD study had a specific dietary protein intervention that
is well described, extending the conclusions of this study
to other dietary interventions including low fat and low
carbohydrate diets warrants caution.
In conclusion, we find that serum cystatin C, unlike serum
creatinine, is not affected by a low protein intake interven-
tion, and may be better filtration marker than creatinine in
Table 4 | Effect of prescribed dietary protein on bias in GFR estimation using the MDRD study equation and the CKD–EPI
cystatin C 2008 study equationa
Equation performance Timing Study A (n=302) Study B (n=124)
DBias eGFRcr (ml/min per 1.73m2) Baseline 0.23 (1.61, 1.15) 0.35 (1.75, 1.10)
DBias eGFRcr (ml/min per 1.73m2) Follow-up 2.77 (4.08, 1.48) 1.37 (2.88, 0.15)
DBias eGFRcys (ml/min per 1.73m2) Baseline 0.60 (2.20, 0.99) 0.50 (0.75, 1.76)
DBias eGFRcys (ml/min per 1.73m2) Follow-up 0.31 (1.75, 1.13) 0.02 (1.70, 1.75)
Abbreviations: CKD, chronic kidney disease; EPI, estimated protein intake; eGFRcr, creatinine-based glomerular filtration rate estimate; eGFRcys, cystatin-based glomerular
filtration rate estimate; GFR, glomerular filtration rate; MDRD, Modification in Diet and Renal Disease.
aDifferences in mean bias between randomized groups (bias in low protein diet group minus bias in usual protein diet group in Study A; very low minus low protein
diet group in Study B). Bias is defined as measured-estimated GFR.
All values are reported as mean and 95% confidence interval. Values highlighted in boldface are statistically significant with Po0.01. P for eGFRcr at follow-up in Study B is 0.08.
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patients with decreased protein intake. Further research on
other non-GFR determinants of cystatin C is needed before
the widespread adoption.
MATERIALS AND METHODS
MDRD study
The details of the entry criteria, design, and results of the
MDRD study have been published previously.7 Briefly, 1782
men and women aged 18 to 70 years with CKD entered a
baseline period to determine eligibility for the trial. On the
basis of measured GFR, the participants were enrolled in
either study A or study B. Participants in study A (n¼ 585)
had entry GFR of 25 to 55ml/min per 1.73m2; participants
in study B (n¼ 255) had entry GFR of 13 to 24ml/min per
1.73m2. Participants in study A were randomly assigned to
either a usual protein diet or a low protein diet. The usual
protein diet contained 1.3 g/kg body weight per day protein
and 16 to 20mg/kg body weight per day phosphorus. The
low protein diet contained 0.575 g/kg body weight per day
protein (with 65% of protein from high biologic value
sources) and 5 to 10mg/kg body weight per day phosphorus.
In study B, the patients were randomly assigned either to the
low protein diet described above or to a very low protein diet
(0.28 g/kg body weight per day) supplemented with a mixed
salt preparation made up of basic amino acids (tyrosine and
threonine) and ketoacid analogs of other essential amino
acids (totaling 0.28 g/kg body weight per day). EPI was
computed from urine urea nitrogen measurements.21
Patients in both studies were also randomized to usual
(p107mmHg for age p60 years, and p113mmHg for age
461 years) versus low (p92mm Hg for age p60 years, and
p98mmHg for age 461 years) blood pressure goals in a
2 2 factorial design.7 For this report, participants in both
blood pressure groups are combined for all analyses.
Measurement of GFR, cystatin C, and creatinine, and
estimation of GFR
GFR was measured as four period urinary clearance of
125I-iothalamate. Samples were assayed for cystatin C with a
particle-enhanced immunonephelometric assay (N Latex
Cystatin C, Dade Behring, IL) in samples stored at –801 C.
The inter- and intraassay coefficients of variation for cystatin C
were 3.2–4.4 and 2.0–3.0%, respectively. Stability in serum
stored at 80 1C has been demonstrated.22,23 Serum creatinine
assays were calibrated to standardized serum creatinine values
at the Cleveland Clinic Research Laboratory. The results of the
calibration procedures have been previously described. GFR
estimates using serum creatinine and cystatin C were calculated
using the MDRD study equation and the CKD–EPI cystatin
equation 2008, respectively.24,25
Descriptive analysis
Descriptive statistics are reported as percentages for catego-
rical data, and mean and standard deviation for normally
distributed continuous data. Continuous variables were
transformed so as to create a linear relationship with log-
transformed cystatin C and creatinine in bivariate analyses.
Sex and race were expressed as binary factors indicating
presence or absence of female sex and black race, respectively.
Differences between groups were tested using the w2-test,
Student t-test, and the Mann–Whitney test as appropriate.
Cross-sectional analysis
The relationships of cystatin C and creatinine with the
predictor variables were investigated by first performing
separate linear regressions to relate log-transformed cystatin
C and creatinine to EPI at the final baseline visit
after controlling for age, sex, and log-transformed GFR. An
increment of 0.2 g/kg per day for protein intake was used for
its clinical applicability (14 g/day for a 70 kg person) and to
maintain consistency with previous work.10 We repeated
these analyses using errors-in-variables regression analysis to
incorporate measurement error in GFR into these models.
A measurement error variance of 0.015 was assumed for
log-transformed GFR based on the analyses of longitudinal
variability in log-transformed baseline GFR.26 GFR measure-
ments were spaced an average of approximately 3 months
apart in the MDRD study.
Longitudinal analysis
The effects of the dietary protein intervention on the change
in measured and eGFR, and serum levels of creatinine and
cystatin C from baseline to 2 years was examined in study
A and study B. For the serum levels of creatinine and cystatin
C, the change was estimated using analysis of covariance,
with the model adjusting for baseline serum levels of the
filtration markers, baseline, and follow-up GFR; and
indicator variables for randomized diet group, respectively.
In this analysis, patients were analyzed according to their
randomized group assignment, irrespective of achieved
protein intake during follow-up.
Performance of GFR estimating equations
The performance of the MDRD study and CKD–EPI cystatin
C 2008 equations was evaluated at baseline and after the
2 year follow-up in both the usual and low protein diet
groups in study A and low and very low protein diet groups
in study B. The mean difference between measured and eGFR
is defined as bias. The mean difference in bias between
randomized groups was compared for both studies
at baseline and after 2 years. The mean change over time in
the mean difference in bias for the two equations was
compared using unpaired t-tests.
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Appendix A1
Table A1 | Characteristics for patients in whom estimated protein intake was available or missing at baseline
Estimated protein intake available (741) Estimated protein intake missing (84)
Mean/N s.d./% Mean/N s.d. (%) P-value
Age (years) 51 13 55.2 12.8 0.37
Female (%) 303 41 23.0 27.4 0.02
White (%) 685 92 75.0 89.3 0.31
Study 0.002
Study A 503 68 71.0 84.5
Study B 238 32 13.0 15.5
Diet 0.006
Usual protein intake 121 16 3.0 3.6
Low protein intake 365 49 51.0 60.7
Very low protein intake 255 34 30.0 35.7
Systolic blood pressure (mmHg) 81 10 81.2 10.3 0.38
Diastolic blood pressure (mmHg) 133 18 138.3 17.8 0.38
Etiology of kidney diseasea 0.33
Polycystic kidney disease 179 24 19.0 22.6
Tubulointerstitial disease 218 29 31.0 36.9
Hypertensive kidney disease 131 18 8.0 9.5
Diabetic nephropathy 23 3 3.0 3.6
Glomerular disease 190 26 23.0 27.4
Laboratory data
Serum creatinine (mg/dl) 3.4 0.9 3.3 0.9 0.16
Cystatin C (mg/l) 3.0 0.5 2.8 0.5 0.003
Measured GFR (ml/min per 1.73m2) 18.5 3.4 20.0 3.4 0.003
Proteinuria (g/day) 1.4 1.7 — — NA
Serum albumin (g/dl) 4.0 0.4 4.1 0.4 0.04
Serum CRP (mg/l) 0.5 0.6 0.4 0.6 0.52
Estimated protein intake (g/kg per day)b 0.9 0.2 — NA
Abbreviations: CRP, C-reactive protein; GFR, glomerular filtration rate.
aData are presented as mean±s.d. for continuous variables and N/percentage for categorical variables.
bProtein intake estimated from urine urea nitrogen excretion rate.
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Appendix A2
Table A2 | Baseline characteristics for patients in whom cystatin C was available or missing at follow-up
Cystatin C available (426) Cystatin C missing (290)
Mean/N s.d./% Mean/N s.d./% P-value
Age (years) 51.8 12.1 52.0 12.2 0.803
Female (%) 156 36.6 131 45.2 0.02
White (%) 24 5.6 30.0 10.3 0.02
Study o0.01
Study A 302 70.9 245 84.5
Study B 124 29.1 45 15.5
Diet 0.06
Usual protein intake 62 14.5 25 8.6
Low protein intake 209 49.1 151 52.1
Very low protein intake 155 36.4 114 39.3
Systolic blood pressure (mmHg) 79.9 10.5 81.7 8.9 0.02
Diastolic blood pressure (mmHg) 130.1 16.9 132.9 18.4 0.04
Etiology of kidney diseasea 0.44
Polycystic kidney disease 99 23.2 79 27.2
Tubulointerstitial disease 127 29.8 87 30.0
Hypertensive kidney disease 78 18.3 50 17.2
Diabetic nephropathy 9 2.1 10 3.5
Glomerular disease 113 26.5 64 22.1
Laboratory data
Serum creatinine (mg/dl) 2.3 0.9 2.1 0.7 o0.01
Cystatin C (mg/l) 2.2 0.7 2.0 0.6 o0.01
Measured GFR (ml/min per 1.73m2) 33.0 11.7 35.9 10.7 o0.01
Proteinuria (g/day) 4.0 0.3 4.1 0.4 0.65
Serum albumin (g/dl) 0.9 1.5 1.0 1.5 0.36
Serum CRP (mg/l) 0.5 0.6 0.5 0.6 0.91
Estimated protein intake (g/kg per day)b 1.0 0.2 1.1 0.2 0.03
Abbreviations: CRP, C-reactive protein; GFR, glomerular filtration rate.
aData are presented as mean±s.d. for continuous variables and N/percentage for categorical variables.
bProtein intake estimated from urine urea nitrogen excretion rate.
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